TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms.
The mechanisms that generate itch are poorly understood at both the molecular and cellular levels despite its clinical importance. To explore the peripheral neuronal mechanisms underlying itch, we assessed the behavioral responses (scratching) produced by s.c. injection of various pruritogens in PLCbeta3- or TRPV1-deficient mice. We provide evidence that at least 3 different molecular pathways contribute to the transduction of itch responses to different pruritogens: 1) histamine requires the function of both PLCbeta3 and the TRPV1 channel; 2) serotonin, or a selective agonist, alpha-methyl-serotonin (alpha-Me-5-HT), requires the presence of PLCbeta3 but not TRPV1, and 3) endothelin-1 (ET-1) does not require either PLCbeta3 or TRPV1. To determine whether the activity of these molecules is represented in a particular subpopulation of sensory neurons, we examined the behavioral consequences of selectively eliminating 2 nonoverlapping subsets of nociceptors. The genetic ablation of MrgprD(+) neurons that represent approximately 90% of cutaneous nonpeptidergic neurons did not affect the scratching responses to a number of pruritogens. In contrast, chemical ablation of the central branch of TRPV1(+) nociceptors led to a significant behavioral deficit for pruritogens, including alpha-Me-5-HT and ET-1, that is, the TRPV1-expressing nociceptor was required, whether or not TRPV1 itself was essential. Thus, TRPV1 neurons are equipped with multiple signaling mechanisms that respond to different pruritogens. Some of these require TRPV1 function; others use alternate signal transduction pathways.
Imamachi
Noritaka
N
Department of Anatomy, University of California, San Francisco, CA 94143, USA.
Park
Goon Ho
GH
Lee
Hyosang
H
Anderson
David J
DJ
Simon
Melvin I
MI
Basbaum
Allan I
AI
Han
Sang-Kyou
SK
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D019332:Endothelin-1 / Q000008:administration & dosage / Q000494:pharmacology; D007267:Injections; D051379:Mice; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D009154:Mutation / Q000235:genetics; D009475:Neurons, Afferent / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D009619:Nociceptors / Q000378:metabolism; D010146:Pain / Q000378:metabolism; D054799:Phospholipase C beta / Q000172:deficiency / Q000378:metabolism; D010812:Physical Stimulation; D020671:Posterior Horn Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D011537:Pruritus / Q000378:metabolism*; D012701:Serotonin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D050916:TRPV Cation Channels / Q000378:metabolism*; D013696:Temperature
D019332:Endothelin-1; D016760:Proto-Oncogene Proteins c-fos; D050916:TRPV Cation Channels; C493921:TRPV1 protein, mouse; C042390:alpha-methylserotonin; D012701:Serotonin; D054799:Phospholipase C beta; C518040:Plcb3 protein, mouse